跳至主要内容
临床试验/NCT04341779
NCT04341779进行中(未招募)不适用

Simplifying Treatment and Monitoring for HIV (STREAM HIV): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa

University of Washington1 个研究点 分布在 1 个国家目标入组 539 人开始时间: 2021年2月4日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
539
试验地点
1
主要终点
Number of Participants With Viral Load Suppression (<200 Copies/ml) and Retained in Care at 72 Weeks

研究概览

简要总结

This study seeks to determine the clinical efficacy and cost effectiveness of implementing an integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence testing and POC viral load (VL) monitoring in improving ART adherence, maintaining durable VL suppression, and improving retention in care among HIV-positive individuals initiating first-line tenofovir disoproxil fumarate (TDF)-based ART in South Africa.

详细描述

This study will be a two-arm, open-label, randomized controlled superiority trial at an HIV clinic in Durban. HIV-positive individuals aged 16 years and above, who are initiating a tenofovir-based, first-line ART will be randomized to receive POC VL testing and POC TFV adherence testing, versus standard-of-care (SoC) viral load testing. The schedule for VL testing and management of VL test results will follow South African guidelines for HIV VL testing after ART initiation. 540 participants will be randomized (1:1) at ART initiation into the intervention arm (routine POC TFV adherence testing with POC VL monitoring) or the standard-of-care (SoC) arm (no objective TFV adherence testing and SoC VL monitoring).

Participants will be followed to compare concentrations between study arms at 24 weeks after ART initiation and a composite outcome of VL suppression and retention in care between the study arms at 72 weeks after ART initiation. The study will use process evaluation data, interviews and focus groups with patients and staff to assess implementation of the POC assays. Micro-costing will be conducted to estimate intervention costs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HIV-positive
  • ≥16 years old
  • Initiating a TDF-based, first-line ART regimen
  • Do not self-report being on an ART regimen in the prior month
  • Willing/able to provide written informed consent

排除标准

  • Does not plan to continue receiving HIV care at the CDC Clinic
  • Per the decision or opinion of the PI (for example, a clinically significant acute or chronic medical condition or circumstances that would make the patient unsuitable for participation or jeopardize the safety or rights of the participant

研究组 & 干预措施

Intervention arm

Experimental

Point-of-care urine adherence testing and Point-of-care viral load testing.

Detailed: Monthly urine TFV testing with adherence counselling for the first 5 months; POC VL testing at Month 6 and 12 with reflex urine TFV testing for VL >200 copies/mL and HIV drug resistance testing if TFV test indicated adherence.

干预措施: Point-of-care viral load testing and tenofovir adherence testing (Combination Product)

Standard-of-care arm

No Intervention

Without POC urine adherence testing and POC viral load testing.

Detailed: routine adherence counseling and lab-based viral load testing.

结局指标

主要结局

Number of Participants With Viral Load Suppression (<200 Copies/ml) and Retained in Care at 72 Weeks

时间窗: 72 weeks after ART initiation

We will measure viral load by a laboratory-based reference assay, performed by the South African National Health Laboratory Services. Viral suppression will be defined as a viral load \<200 copies/mL. This outcome will also include retention in care.

Tenofovir Diphosphate Concentration Level >=700 Fmol/Punch in Dried Blood Spots

时间窗: 72 weeks after ART initiation

We will measure tenofovir-diphosphate concentrations in 3mm dried blood spots using liquid chromatography/tandem mass spectrometry.

次要结局

  • Acceptability of Point-of-care Tenofovir and Viral Load Testing(24 and 72 weeks after ART initiation)
  • Cost-effectiveness of Providing Routine Point-of-care Tenofovir and Viral Load Testing as Compared to Standard-of-care Viral Load Monitoring(24 and 72 weeks after ART initiation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Paul Drain

Professor

University of Washington

研究点 (1)

Loading locations...

相似试验